Skip to main content
Contact Us
Subscribe
E-Edition
85°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Glaukos Corporation Common Stock
(NY:
GKOS
)
103.50
-0.13 (-0.13%)
Official Closing Price
Updated: 5:00 PM EDT, Jul 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Glaukos Corporation Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies
June 25, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell
June 25, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in Upcoming Investor Conferences
May 13, 2025
From
Glaukos Corporation
Via
Business Wire
Earnings Scheduled For April 30, 2025
April 30, 2025
Via
Benzinga
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today
February 24, 2025
Via
Benzinga
Earnings Scheduled For February 20, 2025
February 20, 2025
Via
Benzinga
Peering Into Glaukos's Recent Short Interest
February 12, 2025
Via
Benzinga
How Is The Market Feeling About Glaukos?
January 27, 2025
Via
Benzinga
What 11 Analyst Ratings Have To Say About Glaukos
May 02, 2025
Via
Benzinga
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
May 01, 2025
Via
Benzinga
Glaukos Announces First Quarter 2025 Financial Results
April 30, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
April 23, 2025
From
Glaukos Corporation
Via
Business Wire
$1000 Invested In Glaukos 5 Years Ago Would Be Worth This Much Today
January 23, 2025
Via
Benzinga
What 11 Analyst Ratings Have To Say About Glaukos
December 31, 2024
Via
Benzinga
Forecasting The Future: 7 Analyst Projections For Glaukos
April 16, 2025
Via
Benzinga
Glaukos Announces the Release of its 2024 Sustainability Report
April 16, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30
April 09, 2025
From
Glaukos Corporation
Via
Business Wire
Here's How Much You Would Have Made Owning Glaukos Stock In The Last 5 Years
March 28, 2025
Via
Benzinga
RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution
March 11, 2025
From
Glaukos Corporation
Via
Business Wire
FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery
February 24, 2025
Glaukos' Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its non-invasive treatment potential.
Via
Benzinga
Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™
February 24, 2025
From
Glaukos Corporation
Via
Business Wire
Consumer Sentiment Drops 10%, UnitedHealth Under Investigation: What's Driving Markets Friday?
February 21, 2025
All three major U.S. stock indices are down Friday as traders reacted to several sets of fresh data that raised concerns about the economic outlook.
Via
Benzinga
Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition
February 21, 2025
Glaukos reported Q4 sales of $105.5 million, surpassing estimates, while EPS missed. Analysts see strong growth potential as the company expands its business model.
Via
Benzinga
Wondering what's happening in today's after-hours session?
February 20, 2025
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via
Chartmill
Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results
February 20, 2025
From
Glaukos Corporation
Via
Business Wire
This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
February 19, 2025
Via
Benzinga
Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20
January 23, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform
January 14, 2025
From
Glaukos Corporation
Via
Business Wire
Short Seller Accuses TransMedics Of 'Mafia Style' Scheme, Organ Transplant Company Says Short Seller Manipulating Market
January 13, 2025
TransMedics faces allegations from Scorpion Capital of fraud and organ trafficking, while the company rebuffs the claims as baseless market manipulation.
Via
Benzinga
Topics
Fraud
Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday
December 31, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
